| HOME >> BIOLOGY >> TECHNOLOGY |
Huntsville, AL (PRWEB) March 20, 2013
Eurofins MWG Operon announces the newest entry in their drive to provide ISO-quality research products and services ‘faster than ever.’ Synthetic genes are a rapidly expanding area of business and clients are anxious to accelerate their research in this highly-competitive field of investigation. Customers throughout the US and Canada can now order the new Express Gene service as late as 3:00 p.m. ET for completion just 4 days later - a full day earlier than any advertised service from competitors.
“We’re excited to share our advances in gene synthesis services with our clients. Delivering Express Genes in just 4 days is faster than our competitors are able to advertise. Express Genes joins Overnight DNA sequencing (available for all US locations) and Express Oligos further extending our efforts to be the fastest DNA Company in the US,” stated Martin Kunz, CEO of Eurofins MWG Operon Inc. “The new Express Genes service benefits the research of any institution or company pursuing development in fast cycles.”
“Express Genes is an exciting new offering," stated Helaman Escobar, Director of DNA Sequencing Operations at Eurofins MWG Operon Inc. “Advances in the laboratory have shortened our process for creating high-quality synthetic genes, which includes full DNA sequencing confirmation of the construct. These advances, and production of all gene synthesis under ISO 9001/13485 specifications, make Express Genes a highly competitive entry into the fastest growing segment of the DNA marketplace.” Visit operon.com/express-gene for more information about Express Gene synthetic gene services.
About Eurofins MWG Operon
Eurofins MWG Operon, a member of the Eurofins Group with major offices and production facilities in the United States, Europe, and Asia, is an international provider of DNA sequencing services, DNA synthesis products, and bioinformatics services for aca
'/>"/>
| Source: PRWeb Copyright©2012 Vocus, Inc. All rights reserved |
Related biology technology :
1. Breast Cancer Vaccine Being Developed by Generex Subsidiary Antigen Express to be Featured on Bloomberg Television Today
2. Generex Subsidiary Antigen Express Provides Update on AE37 Cancer Vaccines Clinical & Regulatory Strategy
3. Veracyte Announces Medicare Coverage for Its Afirma® Gene Expression Classifier for Improved Thyroid Nodule Diagnosis
4. Generex Subsidiary Antigen Express Announces Press Conference at American Association for Cancer Research Related to the Immunological Response of its AE37 Vaccine to Prevent Recurrence of Breast Cancer
5. Generex Enhances Antigen Express Scientific Advisory Board for the AE37 Breast Cancer Vaccine with Renowned Breast Cancer Researchers
6. HemoShear Partners with Expression Analysis (EA) to Develop a Human Drug-Induced Vascular Response Database
7. Genedata Expressionist® Established as Data Analysis Platform for Oncological Research
8. Exon skipping to restore gene expression is promising therapeutic strategy for muscular dystrophy
9. Antigen Express AE37 Breast Cancer Vaccine Featured In "Micro-Cap Review" Interview
10. transOMIC technologies Releases Tagged ORF Clones for Protein Expression
11. Free Research Report on Dyax Corp., Ebix, Inc., 8x8, Inc., EnerSys and Express Scripts Holding Co.
| Copyright © 2003-2012 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |